Trial Profile
A Randomized, Double-blind, Active Control, Multicenter Study to Evaluate the Efficacy at Week 52 of Secukinumab Monotherapy Compared With Adalimumab Monotherapy in Patients With Active Psoriatic Arthritis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 28 Apr 2023
Price :
$35
*
At a glance
- Drugs Secukinumab (Primary) ; Adalimumab
- Indications Plaque psoriasis; Psoriatic arthritis
- Focus Registrational; Therapeutic Use
- Acronyms EXCEED; EXCEED 1
- Sponsors Novartis; Novartis Healthcare; Novartis Pharma A.G.; Novartis Pharmaceuticals
- 25 Apr 2023 Results post hoc analysis of the EXCEED study, evaluating Enthesitis in patients with psoriatic arthritis treated with secukinumab or adalimumab, published in the Rheumatology
- 09 Nov 2021 Results of post hoc, descriptive analysis of patients in the EXCEED assessing enthesitis presented at the ACR Convergence 2021
- 05 Jun 2021 Results of a post hoc analysis to explore detailed enthesitis treatment response, including temporal and additional enthesitis presented at the 22nd Annual Congress of the European League Against Rheumatism